Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Improved Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Light Chain (AL) Amyloidosis: A Center for International Blood and Marrow Transplant Registry (CIBMTR) Study

Anita D'Souza, MD, Baldeep Wirk, MD, Mei-Jie Zhang, PhD, Jiaxing Huang, MS, Amrita Krishnan, MD, Tomer M Mark, MD MSc, Cristina J. Gasparetto, MD, Parameswaran N. Hari, MD MRCP, MS

Blood (2014) 124 (21): 193.

https://doi.org/10.1182/blood.V124.21.193.193

Published: 2014

Journal Articles

Meta-Analysis of Pharmacotherapy Vs. Observation for Management of Smoldering Multiple Myeloma

Jayanthi Vijayakumar, MBBS, Jeffrey Jackson, MD MPH, Kwang W Ahn, PhD, Parameswaran N. Hari, MD MRCP, MS

Blood (2014) 124 (21): 4771.

https://doi.org/10.1182/blood.V124.21.4771.4771

Published: 2014

Journal Articles

Ruxolitinib Prior to Allogeneic Stem Cell Transplantation Does Not Adversely Affect Post-Transplant Outcomes

Ahmad Hanif, MD, Parameswaran N. Hari, MD MRCP, MS, Ehab Atallah, MD, Karen-Sue B. Carlson, MD PhD, Marcelo C. Pasquini, MD, Laura C Michaelis, MD

Blood (2014) 124 (21): 1851.

https://doi.org/10.1182/blood.V124.21.1851.1851

Published: 2014

Journal Articles

Disparities in Utilization of Autologous Hematopoietic Progenitor Cell Transplantation for Multiple Myeloma in the US

Luciano J Costa, MD PhD, Jia-Xing Huang, MS, Parameswaran N. Hari, MD MRCP, MS

Blood (2014) 124 (21): 557.

https://doi.org/10.1182/blood.V124.21.557.557

Published: 2014

Journal Articles

Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation

Luciano J Costa, MD PhD, Geoffrey L. Uy, MD, Parameswaran N. Hari, MD MRCP, MS, Mei-Jie Zhang, PhD, Jiaxing Huang, MS, Amrita Krishnan, MD, Tomer M Mark, MD MSc, Anita D'Souza, MD

Blood (2014) 124 (21): 2447.

https://doi.org/10.1182/blood.V124.21.2447.2447

Published: 2014

Journal Articles

A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma

Noopur Raje, MD, Parameswaran N. Hari, MD, MRCP, MS, Heather Landau, MD, Paul G. Richardson, MD, Jacalyn Rosenblatt, MD, Nicole Couture, RN, John F. Lyons, PhD, Gillian Langford, PhD, Murray Yule, MD

Blood (2013) 122 (21): 1976.

https://doi.org/10.1182/blood.V122.21.1976.1976

Published: 2013

Journal Articles

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)

Noopur Raje, MD, Dan T. Vogl, MD, MSCE, Parameswaran N. Hari, MD, MRCP, MS, Sundar Jagannath, MD, Simon S Jones, PhD, Jeffrey G Supko, PhD, Gina Leone, RN, Catherine Wheeler, MD, Robert Z. Orlowski, M.D., Ph.D., Paul G. Richardson, MD, Sagar Lonial, M.D.

Blood (2013) 122 (21): 759.

https://doi.org/10.1182/blood.V122.21.759.759

Published: 2013

Journal Articles

Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study

Noopur Raje, MD, Parameswaran N Hari, MD, MRCP, MS, Dan T. Vogl, MD, MSCE, Sundar Jagannath, MD, Robert Z. Orlowski, M.D., Ph.D., Jeffrey G Supko, PhD, Patricia Stephenson, ScD, Simon S Jones, Catherine Wheeler, MD, Sagar Lonial, MD

Blood (2012) 120 (21): 4061.

https://doi.org/10.1182/blood.V120.21.4061.4061

Published: 2012

Journal Articles

HLA-Identical Sibling-Matched, CD34 + Selected, T Cell Depleted Peripheral Blood Stem Cells Following Myeloablative Conditioning for First or Second Remission Acute Myeloid Leukemia (AML): Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303.

Steven M. Devine, MD, Robert J Soiffer, MD, Marcelo C. Pasquini, MD, Shelly Carter, Parameswaran N Hari, MD, MRCP, MS, Stephanie DeVore, Anthony Stein, Hillard M. Lazarus, MD, Charles Linker, MD, Edward A. Stadtmauer, MD, Carolyn A. Keever-Taylor, PhD, Richard J O'Reilly, MD

Blood (2009) 114 (22): 655.

https://doi.org/10.1182/blood.V114.22.655.655

Published: 2009

NARROW

Improved Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Light Chain (AL) Amyloidosis: A Center for International Blood and Marrow Transplant Registry (CIBMTR) Study

Meta-Analysis of Pharmacotherapy Vs. Observation for Management of Smoldering Multiple Myeloma

Ruxolitinib Prior to Allogeneic Stem Cell Transplantation Does Not Adversely Affect Post-Transplant Outcomes

Disparities in Utilization of Autologous Hematopoietic Progenitor Cell Transplantation for Multiple Myeloma in the US

Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation

A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)

Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study

HLA-Identical Sibling-Matched, CD34 + Selected, T Cell Depleted Peripheral Blood Stem Cells Following Myeloablative Conditioning for First or Second Remission Acute Myeloid Leukemia (AML): Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only